Canaccord raised the firm’s price target on Acadia Pharmaceuticals to $26 from $24 and keeps a Buy rating on the shares. The analyst noted they announced that it received approval for Daybue (trofinetide) for Rett syndrome and provided a significant amount of detail on pricing, and other relevant market variables. We view Daybue’s label as solid with no major restrictions to the product’s use in Rett syndrome. Acadia expects to launch Daybue by the end of April 2023 and shares remain attractively valued.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $21 from $19.40 at Citi
- Acadia Pharmaceuticals price target raised to $28 from $25 at H.C. Wainwright
- Acadia Pharmaceuticals announces FDA approval of DAYBUE for Rett syndrome
- Acadia Pharmaceuticals price target raised to $24 from $20 at Canaccord
- This ETF Has 67% Upside Potential, According to Analysts